Privia Health Group, Inc. (NASDAQ:PRVA) recently saw notable insider activity from its top financial leadership. David Mountcastle, serving as the company's Executive Vice President and Chief Financial Officer, executed a series of transactions between May 1 and May 4, 2026, involving the sale of common stock totaling approximately $209,840.
Details of the Transactions
The selling process was divided into two distinct sessions. On May 1, Mountcastle disposed of 7,179 shares of common stock. These shares were sold at a weighted average price of $25.03 per share, though individual sales within that window ranged from $25.00 to $25.20. This initial transaction accounted for roughly $179,691 in proceeds. On May 4, the CFO sold an additional 1,206 shares at a price of $25.00 per share, adding another $30,150 to the total sale amount.
These sales were preceded by the acquisition of shares through the exercise of stock options. On May 1, Mountcastle exercised options to acquire 7,179 shares at an exercise price of $2.00 per share. Following this, on May 4, he acquired another 1,206 shares at the same $2.00 exercise price. The total value for these acquisitions was approximately $16,770, and all options utilized were fully vested and exercisable.
Market Context and Analyst Outlook
The transactions occurred as Privia Health's stock showed momentum, trading at $24.29, which is close to its 52-week high of $26.51. This activity precedes the company's May 7 earnings report. Financial analysts have recently expressed a constructive view on the company's trajectory.
- Jefferies: Raised its price target for PRVA to $32, pointing toward a strong fourth-quarter performance that exceeded expectations and highlighted business momentum.
- Piper Sandler: Increased its price target to $36, noting impressive results for the fourth quarter of 2025 and 2026 guidance that surpassed expectations in revenue and adjusted EBITDA. Piper Sandler also maintained an Overweight rating based on MSSP analysis and year-over-year growth in adjusted EBITDA.
- Truist Securities: Reiterated a Buy rating with a $33 price target following an investor meeting, signaling confidence in the company's prospects.
- Citizens: Reaffirmed a Market Outperform rating with a $31 price target after correcting a previous calculation error; they kept their full-year 2026 and 2027 EBITDA estimates unchanged.
Current analysis suggests that Privia Health may be undervalued, appearing on lists of undervalued opportunities. This assessment is supported by the company's revenue growth of 22% over the last twelve months while maintaining profitability.